Clinical trial
A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer� NOX-E36 in patients with type 2 diabetes mellitus and albuminuria.
To characterize the effects of 12 weeks treatment with study drug on albumin-creatinine ratio (ACR) in patients with type 2 diabetes and albuminuria
| Category | Value |
|---|---|
| Study start date | 2011-12-06 |